1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Mission Therapeutics Ltd - Product Pipeline Review - 2014

Mission Therapeutics Ltd - Product Pipeline Review - 2014

  • November 2014
  • -
  • Global Markets Direct
  • -
  • 17 pages

Mission Therapeutics Ltd - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Mission Therapeutics Ltd - Product Pipeline Review - 2014’, provides an overview of the Mission Therapeutics Ltd’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Mission Therapeutics Ltd’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Mission Therapeutics Ltd including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Mission Therapeutics Ltd’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Mission Therapeutics Ltd’s pipeline products

Reasons to buy

- Evaluate Mission Therapeutics Ltd’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Mission Therapeutics Ltd in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Mission Therapeutics Ltd’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Mission Therapeutics Ltd and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Mission Therapeutics Ltd
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Mission Therapeutics Ltd and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Mission Therapeutics Ltd - Product Pipeline Review - 2014
Table of Contents

Mission Therapeutics Ltd Snapshot 4
Mission Therapeutics Ltd Overview 4
Key Information 4
Key Facts 4
Mission Therapeutics Ltd - Research and Development Overview 5
Key Therapeutic Areas 5
Mission Therapeutics Ltd - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Mission Therapeutics Ltd - Pipeline Products Glance 9
Mission Therapeutics Ltd - Early Stage Pipeline Products 9
Discovery Products/Combination Treatment Modalities 9
Mission Therapeutics Ltd - Drug Profiles 10
MN-1 10
Product Description 10
Mechanism of Action 10
RandD Progress 10
MN-2 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
MN-3 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
MN-4 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Mission Therapeutics Ltd - Pipeline Analysis 14
Mission Therapeutics Ltd - Pipeline Products by Molecule Type 14
Mission Therapeutics Ltd - Locations And Subsidiaries 15
Head Office 15
Appendix 16
Methodology 16
Coverage 16
Secondary Research 16
Primary Research 16
Expert Panel Validation 16
Contact Us 17
Disclaimer 17

List of Tables

Mission Therapeutics Ltd, Key Information 4
Mission Therapeutics Ltd, Key Facts 4
Mission Therapeutics Ltd - Pipeline by Indication, 2014 6
Mission Therapeutics Ltd - Pipeline by Stage of Development, 2014 7
Mission Therapeutics Ltd - Monotherapy Products in Pipeline, 2014 8
Mission Therapeutics Ltd - Discovery, 2014 9
Mission Therapeutics Ltd - Pipeline by Molecule Type, 2014 14

List of Figures

Mission Therapeutics Ltd - Pipeline by Top 10 Indication, 2014 6

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.